Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study

Nuclear Medicine and Biology

Volumn 35, Issue 4, 2008, Pages 459-466

  de Vries, Erik F J ^a   Doorduin, Janine ^a   Vellinga, Namkje A R ^a   van Waarde, Aren ^a   Dierckx, Rudi A ^a   Klein, Hans C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

11C verapamil; Blood brain barrier; Celecoxib; Nonsteroidal anti inflammatory drug; P glycoprotein; Positron emission tomography

Indexed keywords

CARBON 11; CELECOXIB; CYCLOSPORIN A; GLYCOPROTEIN P; TRACER; VERAPAMIL;

ARTICLE; CONTROLLED STUDY; CYTOSTASIS; DRUG MECHANISM; EFFUSION; EX VIVO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; NONHUMAN; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PROTEIN FUNCTION; RAT;

ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT, ACTIVE; BRAIN; BRAIN CHEMISTRY; CARBON RADIOISOTOPES; CYCLOSPORINE; MALE; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; SULFONAMIDES; TISSUE DISTRIBUTION; VERAPAMIL;

EID: 43049157982     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.01.005     Document Type: Article

References (25)

1. Bart J., Groen H.J., Hendrikse N.H., van der Graaf W.T., Vaalburg W., and de Vries E.G. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 26 (2000) 449-462
2. Elsinga P.H., Hendrikse N.H., Bart J., Vaalburg W., and van Waarde A. PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des 10 (2004) 1493-1503
3. Wang R.B., Kuo C.L., Lien L.L., and Lien E.J. Structure-activity relationship: analyses of P-glycoprotein substrates and inhibitors. J Clin Pharm Ther 28 (2003) 203-228
4. List A.F., Kopecky K.J., Willman C.L., Head D.R., Persons D.L., Slovak M.L., et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98 (2001) 3212-3220
5. Ferry D.R., Traunecker H., and Kerr D.J. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A (1996) 1070-1081
6. Awara W.M., El Sisi A.E., El Sayad M.E., and Goda A.E. The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?. Pharmacol Res 50 (2004) 487-498
7. Hashitani S., Urade M., Nishimura N., Maeda T., Takaoka K., Noguchi K., et al. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int J Oncol 23 (2003) 665-672
8. Ponthan F., Wickstrom M., Gleissman H., Fuskevag O.M., Segerstrom L., Sveinbjornsson B., et al. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res 13 (2007) 1036-1044
9. van Wijngaarden J., van Beek E., van Rossum G., van der Bent C., Hoekman K., van der Pluijm G., et al. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. Eur J Cancer 43 (2007) 433-442
10. Muller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Muller B., et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11 (2006) 680-684
11. Muller N., Riedel M., Scheppach C., Brandstatter B., Sokullu S., Krampe K., et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 159 (2002) 1029-1034
12. Fisher G.A., Lum B.L., Hausdorff J., and Sikic B.I. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 32A (1996) 1082-1088
13. Zhu H.J., Wang J.S., Markowitz J.S., Donovan J.L., Gibson B.B., and Devane C.L. Risperidone and paliperidone inhibit P-glycoprotein activity in vitro. Neuropsychopharmacology 32 (2007) 757-764
14. Weiss J., Dormann S.M., Martin-Facklam M., Kerpen C.J., Ketabi-Kiyanvash N., and Haefeli W.E. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305 (2003) 197-204
15. Prabhakaran J., Majo V.J., Simpson N.R., Van Heertum R.L., Mann J.J., and Kumar J.S.D. Synthesis of [C-11]celecoxib: a potential PET probe for imaging COX-2 expression. J Label Compd Radiopharm 48 (2005) 887-895
16. Prabhakaran J., Underwood M.D., Parsey R.V., Arango V., Majo V.J., Simpson N.R., et al. Synthesis and in vivo evaluation of [18F]-4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesul fonamide as a PET imaging probe for COX-2 expression. Bioorg Med Chem 15 (2007) 1802-1807
17. Garti N., Avrahami M., and Aserin A. Improved solubilization of Celecoxib in U-type nonionic microemulsions and their structural transitions with progressive aqueous dilution. J Colloid Interface Sci 299 (2006) 352-365
18. Hendrikse N.H. Monitoring interactions at ATP-dependent drug efflux pumps. Curr Pharm Des 6 (2000) 1653-1668
19. Wegman T.D., Maas B., Elsinga P.H., and Vaalburg W. An improved method for the preparation of [11C]verapamil. Appl Radiat Isot 57 (2002) 505-507
20. Paulson S.K., Zhang J.Y., Breau A.P., Hribar J.D., Liu N.W., Jessen S.M., et al. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab Dispos 28 (2000) 514-521
21. Lacroix S., and Rivest S. Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain. J Neurochem 70 (1998) 452-466
22. Bart J., Hollema H., Groen H.J., de Vries E.G., Hendrikse N.H., Sleijfer D.T., et al. The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer 40 (2004) 2064-2070
23. Cekic D., Bellarosa C., Garcia-Mediavilla M.V., Rigato I., Pascolo L., Ostrow J.D., et al. Upregulation in the expression of multidrug resistance protein Mrp1 mRNA and protein by increased bilirubin production in rat. Biochem Biophys Res Commun 311 (2003) 891-896
24. Niwa T., Yamamoto S., Saito M., Shiraga T., and Takagi A. Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. Yakugaku Zasshi 127 (2007) 209-216
25. Tracy T.S., Korzekwa K.R., Gonzalez F.J., and Wainer I.W. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol 47 (1999) 545-552